The search for effective therapeutics has been unyielding in the relentless
battle against the COVID-19 pandemic. A potential drug candidate is 2-deoxyD-glucose (2-DG), which has been evaluated as a polypharmacological agent for
antiviral therapy due to its influence on the glycolytic pathway. This chapter delves
into the promising role of 2-deoxy-D-glucose (2-DG) as a potential anti-viral drug.
With a focus on the biochemical and pharmacological aspects, this chapter explores
how 2-DG may disrupt the viral life cycle and modulate host immune responses. An
in-depth analysis of the current scientific evidence, including preclinical studies and
clinical trials, will be highlighted to shed light on the drug's efficacy, safety, and
potential as a treatment option. Furthermore, the challenges and prospects of 2-DG in
the context of COVID-19 management will be elaborated. The COVID-19 pandemic
has posed unprecedented challenges to global healthcare systems, demanding swift and
innovative approaches to combat the virus. Amid this backdrop, the utilization of 2-
deoxy-D-glucose (2-DG) as an anti-COVID-19 drug has emerged as a promising
avenue for research and therapeutic development. This chapter offers an exhaustive
exploration of the potential of 2-DG in the context of COVID-19 treatment.
Additionally, action mechanisms and safety concerns associated with administering 2-
DG in treating COVID-19 will be reviewed. This chapter aims to equip readers with a
comprehensive understanding of 2-DG's role in the fight against COVID-19 and its
place in the evolving the landscape of antiviral therapeutics.
Keywords: Antiviral therapy, Glycolytic, Polypharmacological agent, SARSCoV-2, 2-DG.
